Reviewing Marker Therapeutics Inc. (MRKR)’s and Taiwan Liposome Company Ltd. (NASDAQ:TLC)’s results

We will be comparing the differences between Marker Therapeutics Inc. (NASDAQ:MRKR) and Taiwan Liposome Company Ltd. (NASDAQ:TLC) as far as institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Marker Therapeutics Inc. N/A 11594.95 15.08M -1.28 0.00
Taiwan Liposome Company Ltd. N/A 0.00 N/A -0.51 0.00

Demonstrates Marker Therapeutics Inc. and Taiwan Liposome Company Ltd. earnings per share, top-line revenue and valuation.


Table 2 has Marker Therapeutics Inc. and Taiwan Liposome Company Ltd.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Marker Therapeutics Inc. 0.00% -662.2% -295.8%
Taiwan Liposome Company Ltd. 0.00% 0% 0%

Insider & Institutional Ownership

Roughly 43.5% of Marker Therapeutics Inc. shares are held by institutional investors while 2.46% of Taiwan Liposome Company Ltd. are owned by institutional investors. Insiders held 22.8% of Marker Therapeutics Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Marker Therapeutics Inc. -3.11% 17.96% -10.86% -12.11% 96.23% 12.43%
Taiwan Liposome Company Ltd. -0.5% -2.14% -6.74% 0% 0% 8.18%

For the past year Marker Therapeutics Inc. was more bullish than Taiwan Liposome Company Ltd.


Taiwan Liposome Company Ltd. beats on 4 of the 7 factors Marker Therapeutics Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.